The prognostic value of the systemic immune-inflammation index (SII) has been shown in various types of cancers. We aimed to evaluate the predictive values in brain metastases from lung adenocarcinoma with status of EGFR mutations. We, retrospectively, examined 310 patients with brain metastases from lung adenocarcinoma with status of EGFR mutations. SII was calculated using P * N/L, where P, N, and L, respectively refer to peripheral blood lymphocyte, neutrophil, and platelet counts. The cut-off value of SII was assessed by area under the curve (AUC). The log-rank test and Cox proportional hazard model were used to confirm the impact of SII and other variables on survival. The SII value ≤ 1218.81 was associated with prolonged survival in patients with brain metastases from lung adenocarcinoma in both variable and multivariable analysis In patients with EGFR mutations, the SII had statistical effect on OS only in invariable test. While, for patients with wild-type EGFR, SII achieved statistically significant differences both in variable and multivariable analyses. SII is an independent prognostic factor in brain metastases from lung adenocarcinoma. SII may have varying prognostic effects on patients with and without EGFR mutations and is a promising variable for the future prognostic systems.

中文翻译：

---

全身免疫炎症指数在具有不同EGFR突变的肺腺癌脑转移中的预后作用。

全身免疫炎症指数（SII）的预后价值已在各种类型的癌症中显示。我们旨在评估具有EGFR突变状态的肺腺癌脑转移的预测价值。我们回顾性地检查了310例患有EGFR突变状态的肺腺癌脑转移患者。使用P * N / L计算SII，其中P，N和L分别指外周血淋巴细胞，中性粒细胞和血小板计数。SII的临界值通过曲线下面积（AUC）进行评估。使用对数秩检验和Cox比例风险模型来确认SII和其他变量对生存的影响。SII值≤1218。在变量和多变量分析中，81均与肺腺癌脑转移患者的生存期延长有关。在EGFR突变患者中，SII仅在恒定检验中对OS有统计学影响。而对于野生型EGFR患者，SII在可变和多变量分析中均达到了统计学上的显着差异。SII是肺腺癌脑转移的独立预后因素。SII对有或没有EGFR突变的患者可能有不同的预后影响，并且对于未来的预后系统而言，它是一个有希望的变量。SII是肺腺癌脑转移的独立预后因素。SII对有或没有EGFR突变的患者可能有不同的预后影响，并且对于未来的预后系统而言，它是一个有希望的变量。SII是肺腺癌脑转移的独立预后因素。SII对有或没有EGFR突变的患者可能有不同的预后影响，并且对于未来的预后系统而言，它是一个有希望的变量。